Literature DB >> 11468032

A double blind parallel group placebo controlled comparison of sedative and mnesic effects of etifoxine and lorazepam in healthy subjects [corrected].

J Micallef1, C Soubrouillard, F Guet, M E Le Guern, C Alquier, B Bruguerolle, O Blin.   

Abstract

This paper describes the psychomotor and mnesic effects of single oral doses of etifoxine (50 and 100 mg) and lorazepam (2 mg) in healthy subjects. Forty-eight healthy subjects were included in this randomized double blind, placebo controlled parallel group study [corrected]. The effects of drugs were assessed by using a battery of subjective and objective tests that explored mood and vigilance (Visual Analog Scale), attention (Barrage test), psychomotor performance (Choice Reaction Time) and memory (digit span, immediate and delayed free recall of a word list). Whereas vigilance, psychomotor performance and free recall were significantly impaired by lorazepam, neither dosage of etifoxine (50 and 100 mg) produced such effects. These results suggest that 50 and 100 mg single dose of etifoxine do not induce amnesia and sedation as compared to lorazepam.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468032     DOI: 10.1046/j.1472-8206.2001.00025.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  11 in total

Review 1.  A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.

Authors:  Cara Tannenbaum; Amélie Paquette; Sarah Hilmer; Jayna Holroyd-Leduc; Ryan Carnahan
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

2.  The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis.

Authors:  Jean Luc do Rego; David Vaudry; Hubert Vaudry
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

3.  A Finite Mixture Item Response Theory Model for Continuous Measurement Outcomes.

Authors:  Cengiz Zopluoglu
Journal:  Educ Psychol Meas       Date:  2019-06-27       Impact factor: 2.821

4.  Etifoxine improves peripheral nerve regeneration and functional recovery.

Authors:  Christelle Girard; Song Liu; Françoise Cadepond; David Adams; Catherine Lacroix; Marc Verleye; Jean-Marie Gillardin; Etienne-Emile Baulieu; Michael Schumacher; Ghislaine Schweizer-Groyer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

5.  Effects of word frequency on recall memory following lorazepam, alcohol, and lorazepam alcohol interaction in healthy volunteers.

Authors:  Sompop Soo-ampon; Noppamars Wongwitdecha; Surin Plasen; Ian Hindmarch; Julia Boyle
Journal:  Psychopharmacology (Berl)       Date:  2004-04-29       Impact factor: 4.530

Review 6.  Anxiety disorders and GABA neurotransmission: a disturbance of modulation.

Authors:  Philippe Nuss
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-17       Impact factor: 2.570

Review 7.  Analgesic strategies aimed at stimulating the endogenous production of allopregnanolone.

Authors:  Pierrick Poisbeau; Anne Florence Keller; Maya Aouad; Nisrine Kamoun; Ghislaine Groyer; Michael Schumacher
Journal:  Front Cell Neurosci       Date:  2014-06-17       Impact factor: 5.505

Review 8.  Etifoxine for pain patients with anxiety.

Authors:  Yun Mi Choi; Kyung Hoon Kim
Journal:  Korean J Pain       Date:  2015-01-02

9.  Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial.

Authors:  Dan J Stein
Journal:  Adv Ther       Date:  2015-01-27       Impact factor: 3.845

10.  Differential effects of the translocator protein 18 kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment.

Authors:  Lisa-Marie Brunner; Franziska Maurer; Kevin Weber; Johannes Weigl; Vladimir M Milenkovic; Rainer Rupprecht; Caroline Nothdurfter; Andreas Mühlberger
Journal:  Psychopharmacology (Berl)       Date:  2022-03-12       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.